McKesson at a glance
McKesson Corporation is a healthcare distribution and services company headquartered in Irving, Texas. It connects pharmaceutical manufacturers with pharmacies, hospitals, health systems, community oncology practices, and other care providers. Brian S. Tyler is chief executive officer. The company traces its history to 1833 and reported more than 43,000 employees worldwide as of March 31, 2026.
For the fiscal year ended March 31, 2026, McKesson reported $403.4 billion in consolidated revenue, up 12% year over year. It also reported $6.2 billion in operating cash flow and $5.4 billion in free cash flow. These figures describe a company with enormous transaction volume but economics that differ sharply from a drug manufacturer: McKesson earns primarily by distributing products and providing services, not by discovering medicines or owning a pharmaceutical pipeline.
How McKesson makes money
McKesson's core business is pharmaceutical distribution. It buys medicines and related products from manufacturers, manages inventory and regulated logistics, and delivers them to customers. The spread and service fees on an individual shipment can be small, so scale, purchasing discipline, warehouse utilization, order accuracy, and working-capital management are central to profitability.
McKesson reported four segments for fiscal 2026. North American Pharmaceutical generated $336.7 billion in revenue. Oncology & Multispecialty generated $48.4 billion through specialty distribution and provider services. Prescription Technology Solutions generated $5.8 billion from access, affordability, third-party logistics, and technology services. Medical-Surgical Solutions generated $11.5 billion by serving alternate sites of care with supplies and related services.
The 2026 Form 10-K states that distribution and retail businesses represented about 98% of consolidated revenue, while services represented about 2%. That mix explains why revenue is very large relative to operating profit. Investors therefore need to examine segment operating profit, cash flow, customer concentration, and working capital in addition to headline revenue.
Growth strategy
Management is directing more investment toward oncology, multispecialty care, and biopharma services. Oncology & Multispecialty was McKesson's fastest-growing reported segment in fiscal 2026, with revenue up 31%. The company has expanded its provider network through investments in businesses including PRISM Vision and Core Ventures, while its US Oncology Network supports community-based cancer care.
Prescription Technology Solutions is another higher-margin growth area. Its tools help patients access and afford medicines and help manufacturers manage patient-support and distribution programs. This is different from the medical-claims clearinghouse operated by Change Healthcare. McKesson separated from Change Healthcare years before UnitedHealth Group acquired that company, so Change Healthcare should not be presented as a current McKesson subsidiary.
Portfolio simplification is the other side of the strategy. McKesson completed its exit from European operations in January 2026 and is pursuing a separation of Medical-Surgical Solutions. If completed, that transaction would leave a more focused company centered on North American pharmaceutical distribution, oncology and multispecialty services, and prescription technology.
Competitive position
McKesson's principal distribution advantages are scale, nationwide infrastructure, regulatory capability, supplier and customer relationships, and high order accuracy. A new entrant would need substantial capital, controlled-substance compliance systems, refrigerated and specialty logistics, and enough volume to operate efficiently. Cencora and Cardinal Health are the closest large US distribution competitors.
The moat is meaningful but does not eliminate risk. Large customers can negotiate aggressively, branded and generic drug mix can change, suppliers can alter commercial terms, and customer bankruptcies can create losses. Drug-pricing policy, 340B rules, opioid-related litigation, cybersecurity, and the execution of acquisitions or separations can also affect results. Because the core business runs on thin margins, small changes in volume, pricing, or costs can have an outsized effect on profit.
Financial takeaway
McKesson's revenue increased from $308.95 billion in fiscal 2024 to $359.1 billion in fiscal 2025 and $403.4 billion in fiscal 2026. The latest year included $38.38 in diluted earnings per share and $39.11 in adjusted diluted earnings per share. Management established fiscal 2027 adjusted EPS guidance of $43.80 to $44.60, while emphasizing continued growth in oncology, multispecialty, and biopharma services.
The most useful way to read McKesson is as a scale distributor with a growing set of service platforms. Revenue shows the volume moving through the network; segment profit and cash flow show how much economic value McKesson retains. The key strategic question is whether faster-growing service businesses can increase the quality of earnings without weakening the operational discipline of pharmaceutical distribution.
